The BioCentury Show
The BioCentury Show
BioCentury
Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem
31 minutes Posted Oct 16, 2025 at 11:00 pm.
Introduction
Degraders' Appeal
Glue vs. Heterobifunctional
Translating a New Modality
Partnerships
0:00
31:33
Download MP3
Show notes
Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of biopharma’s most closely watched new therapeutic modalities, Kymera is now over nine years into its story, with multiple pharma partnerships and a wholly owned pipeline, including a STAT6 degrader that produced promising data in June. In conversation with BioCentury’s Selina Koch...